XERS logo

Xeris Biopharma Holdings, Inc. (XERS) EBITDA

Annual EBITDA:

-$13.99M+$9.74M(+41.04%)
December 31, 2024

Summary

  • As of today, XERS annual EBITDA is -$13.99 million, with the most recent change of +$9.74 million (+41.04%) on December 31, 2024.
  • During the last 3 years, XERS annual EBITDA has risen by +$99.67 million (+87.69%).
  • XERS annual EBITDA is now -6.90% below its all-time high of -$13.09 million, reached on December 31, 2016.

Performance

XERS EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherXERSincome statement metrics

Quarterly EBITDA:

$9.92M+$2.27M(+29.74%)
September 30, 2025

Summary

  • As of today, XERS quarterly EBITDA is $9.92 million, with the most recent change of +$2.27 million (+29.74%) on September 30, 2025.
  • Over the past year, XERS quarterly EBITDA has increased by +$19.69 million (+201.55%).
  • XERS quarterly EBITDA is now at all-time high.

Performance

XERS Quarterly EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherXERSincome statement metrics

TTM EBITDA:

$22.43M+$19.69M(+718.05%)
September 30, 2025

Summary

  • As of today, XERS TTM EBITDA is $22.43 million, with the most recent change of +$19.69 million (+718.05%) on September 30, 2025.
  • Over the past year, XERS TTM EBITDA has increased by +$54.85 million (+169.20%).
  • XERS TTM EBITDA is now at all-time high.

Performance

XERS TTM EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherXERSincome statement metrics

EBITDA Formula

EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization

XERS EBITDA Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1Y1 Year+41.0%+201.6%+169.2%
3Y3 Years+87.7%+163.5%+123.8%
5Y5 Years+88.1%+179.0%+123.7%

XERS EBITDA Highs & Lows

PeriodPeriodAnnual vs HighAnnual vs HighAnnual vs LowAnnual vs LowQuarter. vs HighQuarter. vs HighQuarter. vs LowQuarter. vs LowTTM vs HighTTM vs HighTTM vs LowTTM vs Low
3Y3-Yearat high+87.7%at high+163.5%at high+123.8%
5Y5-Yearat high+88.1%at high+126.1%at high+120.0%
All-TimeAll-Time-6.9%+88.1%at high+126.1%at high+118.1%

XERS EBITDA History

DateAnnualQuarterlyTTM
Sep 2025
-
$9.92M(+29.7%)
$22.43M(+718.1%)
Jun 2025
-
$7.65M(>+9900.0%)
$2.74M(+127.6%)
Mar 2025
-
$53.00K(-98.9%)
-$9.94M(+52.7%)
Dec 2024
-$13.99M(+41.0%)
$4.81M(+149.3%)
-$21.02M(+35.2%)
Sep 2024
-
-$9.77M(-94.1%)
-$32.41M(-33.9%)
Jun 2024
-
-$5.03M(+54.4%)
-$24.20M(+23.9%)
Mar 2024
-
-$11.03M(-67.6%)
-$31.79M(-3.0%)
Dec 2023
-$23.73M(+65.8%)
-$6.58M(-323.0%)
-$30.85M(+14.2%)
Sep 2023
-
-$1.56M(+87.7%)
-$35.94M(+28.1%)
Jun 2023
-
-$12.62M(-25.0%)
-$50.01M(+6.1%)
Mar 2023
-
-$10.10M(+13.5%)
-$53.25M(+21.4%)
Dec 2022
-$69.31M(+39.0%)
-$11.67M(+25.4%)
-$67.78M(+28.0%)
Sep 2022
-
-$15.63M(+1.4%)
-$94.09M(+8.2%)
Jun 2022
-
-$15.85M(+35.6%)
-$102.49M(+8.4%)
Mar 2022
-
-$24.63M(+35.1%)
-$111.90M(-8.2%)
Dec 2021
-$113.67M
-$37.97M(-58.0%)
-$103.38M(-24.0%)
Sep 2021
-
-$24.04M(+4.9%)
-$83.40M(-16.0%)
DateAnnualQuarterlyTTM
Jun 2021
-
-$25.27M(-56.9%)
-$71.93M(-4.9%)
Mar 2021
-
-$16.10M(+10.5%)
-$68.55M(+14.7%)
Dec 2020
-$79.12M(+32.8%)
-$18.00M(-43.3%)
-$80.38M(+15.2%)
Sep 2020
-
-$12.56M(+42.6%)
-$94.80M(+15.3%)
Jun 2020
-
-$21.89M(+21.6%)
-$111.98M(+9.6%)
Mar 2020
-
-$27.93M(+13.8%)
-$123.93M(-2.2%)
Dec 2019
-$117.80M(-105.9%)
-$32.42M(-9.0%)
-$121.30M(-11.3%)
Sep 2019
-
-$29.74M(+12.1%)
-$109.02M(-15.7%)
Jun 2019
-
-$33.84M(-33.7%)
-$94.22M(-29.7%)
Mar 2019
-
-$25.30M(-25.6%)
-$72.66M(-23.1%)
Dec 2018
-$57.22M(-117.3%)
-$20.14M(-34.8%)
-$59.02M(-51.8%)
Sep 2018
-
-$14.94M(-21.7%)
-$38.88M(-23.4%)
Jun 2018
-
-$12.28M(-5.2%)
-$31.52M(-63.8%)
Mar 2018
-
-$11.67M(-54.1%)
-$19.24M(-57.9%)
Dec 2017
-$26.33M(-101.1%)
-
-
Sep 2017
-
-$7.57M(-64.2%)
-$12.18M(-164.2%)
Mar 2017
-
-$4.61M
-$4.61M
Dec 2016
-$13.09M
-
-

FAQ

  • What is Xeris Biopharma Holdings, Inc. annual EBITDA?
  • What is the all-time high annual EBITDA for Xeris Biopharma Holdings, Inc.?
  • What is Xeris Biopharma Holdings, Inc. annual EBITDA year-on-year change?
  • What is Xeris Biopharma Holdings, Inc. quarterly EBITDA?
  • What is the all-time high quarterly EBITDA for Xeris Biopharma Holdings, Inc.?
  • What is Xeris Biopharma Holdings, Inc. quarterly EBITDA year-on-year change?
  • What is Xeris Biopharma Holdings, Inc. TTM EBITDA?
  • What is the all-time high TTM EBITDA for Xeris Biopharma Holdings, Inc.?
  • What is Xeris Biopharma Holdings, Inc. TTM EBITDA year-on-year change?

What is Xeris Biopharma Holdings, Inc. annual EBITDA?

The current annual EBITDA of XERS is -$13.99M

What is the all-time high annual EBITDA for Xeris Biopharma Holdings, Inc.?

Xeris Biopharma Holdings, Inc. all-time high annual EBITDA is -$13.09M

What is Xeris Biopharma Holdings, Inc. annual EBITDA year-on-year change?

Over the past year, XERS annual EBITDA has changed by +$9.74M (+41.04%)

What is Xeris Biopharma Holdings, Inc. quarterly EBITDA?

The current quarterly EBITDA of XERS is $9.92M

What is the all-time high quarterly EBITDA for Xeris Biopharma Holdings, Inc.?

Xeris Biopharma Holdings, Inc. all-time high quarterly EBITDA is $9.92M

What is Xeris Biopharma Holdings, Inc. quarterly EBITDA year-on-year change?

Over the past year, XERS quarterly EBITDA has changed by +$19.69M (+201.55%)

What is Xeris Biopharma Holdings, Inc. TTM EBITDA?

The current TTM EBITDA of XERS is $22.43M

What is the all-time high TTM EBITDA for Xeris Biopharma Holdings, Inc.?

Xeris Biopharma Holdings, Inc. all-time high TTM EBITDA is $22.43M

What is Xeris Biopharma Holdings, Inc. TTM EBITDA year-on-year change?

Over the past year, XERS TTM EBITDA has changed by +$54.85M (+169.20%)
On this page